IBRANCE® (palbociclib) is the first FDA-approved medication in a class of therapy called CDK 4/6 inhibitors. Taken in combination with certain hormonal therapies, IBRANCE works to put the brakes on cell growth and division in hormone receptor positive, HER2- metastatic breast cancer.

IBRANCE is taken with hormonal therapy and is used to treat hormone receptor positive, HER2- metastatic breast cancer. In combination with letrozole (sometimes called Femara®), IBRANCE is for postmenopausal women as their first hormonal based therapy. In combination with fulvestrant (known as Faslodex®), IBRANCE is for women who have previously received…

*The information provided on this website is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Reliance on any information provided by this website is solely at your own risk. The owners, contributors, authors, and publishers of this website are not liable for any losses, injuries, or damages arising from the use of the information on this website.*

Pin It on Pinterest

Share This